David Planchard, Thoracic Oncologist, Professor at the University Paris Saclay and Head of the Thoracic Cancer Group at the Gustave Roussy, shared a post on LinkedIn:
“It was an honor to present, on behalf of the co-investigators, the planned OS results from FLAURA2 ph III at WCLC25. These results confirm a shift in our first-line practice for our EGFRm patients, marking the first time a study has achieved a significant benefit mOS of 4Y.”
More posts featuring David Planchard on OncoDaily.
